RESVERLOGIX CORP. ESTABLISHES SUBSIDIARY: RVX THERAPEUTICS INC.

Resverlogix Corp. (TSX:RVX) is pleased to announce that it has established a wholly-owned subsidiary called RVX Therapeutics Inc. for business and strategic objectives. Resverlogix Corp. will still hold its primary asset -- NEXVAS(TM) technology for cardiovascular applications. The purpose of RVX Therapeutics is to hold non-core assets (TGF-Beta Shield(TM) and others) that will develop separately from the NEXVAS technology. An independent third-party valuation group has been hired to provide the appropriate valuation for the transfer of this technology. This process is planned to occur imminently.

CCNMathews (http://www.ccnmatthews.com/news/releases/show.jsp?action=showRelease&actionFor=550210)

(http://www.tradingmarkets.com/tm.site/news/BREAKING%20NEWS/24798/)